C

Corline Biomedical AB
STO:CLBIO

Watchlist Manager
Corline Biomedical AB
STO:CLBIO
Watchlist
Price: 17 SEK -1.16% Market Closed
Market Cap: 416.3m SEK

Wall Street
Price Targets

CLBIO Price Targets Summary
Corline Biomedical AB

Wall Street analysts forecast CLBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CLBIO is 32.64 SEK with a low forecast of 32.32 SEK and a high forecast of 33.6 SEK.

Lowest
Price Target
32.32 SEK
90% Upside
Average
Price Target
32.64 SEK
92% Upside
Highest
Price Target
33.6 SEK
98% Upside
Corline Biomedical AB Competitors:
Price Targets
SNT
Syntara Ltd
286% Upside
XERS
Xeris Biopharma Holdings Inc
64% Upside
GLAND
Gland Pharma Ltd
24% Upside
002603
Shijiazhuang Yiling Pharmaceutical Co Ltd
5% Upside
4506
Sumitomo Pharma Co Ltd
10% Downside
NATCOPHARM
Natco Pharma Ltd
4% Upside
069620
Daewoong Pharma
14% Upside
002422
Sichuan Kelun Pharmaceutical Co Ltd
32% Upside

Revenue
Forecast

Revenue Estimate
Corline Biomedical AB

For the last 10 years the compound annual growth rate for Corline Biomedical AB's revenue is 19%. The projected CAGR for the next 4 years is 79%.

19%
Past Growth
79%
Estimated Growth
Estimates Accuracy
-32%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Corline Biomedical AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-25%
Average Miss

Net Income
Forecast

Net Income Estimate
Corline Biomedical AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CLBIO's stock price target?
Price Target
32.64 SEK

According to Wall Street analysts, the average 1-year price target for CLBIO is 32.64 SEK with a low forecast of 32.32 SEK and a high forecast of 33.6 SEK.

What is Corline Biomedical AB's Revenue forecast?
Projected CAGR
79%

For the last 10 years the compound annual growth rate for Corline Biomedical AB's revenue is 19%. The projected CAGR for the next 4 years is 79%.

Back to Top